Format

Send to

Choose Destination
Rheumatology (Oxford). 2017 Feb;56(2):178-186. doi: 10.1093/rheumatology/kew212. Epub 2016 May 13.

Vitamin D treatment for connective tissue diseases: hope beyond the hype?

Author information

1
Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester.
2
NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
3
Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester ian.bruce@manchester.ac.uk.

Abstract

The prevalence of vitamin D deficiency is increased among patients with CTDs. The active form of vitamin D (calcitriol) is a potent regulator of the immune system and may suppress inflammatory responses. This has led to claims that vitamin D may be a safe treatment, or a treatment adjunct, to reduce systemic inflammation in this patient population. It is important to note, however, that there is insufficient evidence from robust clinical trials to support these novel uses for vitamin D. In this review we examine the potential role of vitamin D as a treatment adjunct for CTDs. We will discuss how vitamin D may modulate the immune response and review the current evidence for using vitamin D to treat CTDs and their associated co-morbidities. We conclude that while there is much excitement about vitamin D in this context, further well-designed trials are needed to demonstrate its efficacy in the treatment of patients with CTDs.

KEYWORDS:

cardiovascular disease; connective tissue disease; inflammation; systemic lupus erythematosus; vitamin D

PMID:
27179106
PMCID:
PMC5854035
DOI:
10.1093/rheumatology/kew212
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center